1022-P: Efficacy of Sliding Scale Insulin for Inpatient Glycemic Control in a Multinational Propensity-Matched Cohort Study
Sliding scale insulin (SSI) continues to be widely used for glycemic management of inpatients with T2D despite condemnation in clinical guidelines. To confirm the accuracy of this clinical guideline recommendation, we determined the efficacy and safety of using SSI for the management hyperglycemia o...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2020-06, Vol.69 (Supplement_1) |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 69 |
| creator | MIGDAL, ALEXANDRA FORTIN, CHARLIE GUO, YI HOCHBERG, IRIT MAGEE, MICHELLE F. PASQUEL, FRANCISCO J. UMPIERREZ, GUILLERMO E. |
| description | Sliding scale insulin (SSI) continues to be widely used for glycemic management of inpatients with T2D despite condemnation in clinical guidelines. To confirm the accuracy of this clinical guideline recommendation, we determined the efficacy and safety of using SSI for the management hyperglycemia of non-critical patients with T2D in a large multinational, propensity-matched cohort study. A total of 53,516 patients with ICD 9/10 code of T2D were included in the dataset. Patients were categorized as having received SSI only vs. basal insulin, and were matched according to age, BMI, Charlson Comorbidity Index, and admission blood glucose (BG). Among patients with admission BG |
| doi_str_mv | 10.2337/db20-1022-P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2419452524</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2419452524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c644-e09caf3a42ecaca36c3c972718f0ae25a429d7d24c7dfadcd15653e86d4210313</originalsourceid><addsrcrecordid>eNotkE1LAzEURYMoWKsr_0DApYzmY2bScSel1kKLhXbhLsR82JQ0qUlmMfjnTam8xXtwD4_LAeAeoydCKXtWXwRVGBFSrS_ACHe0qyhhn5dghBAmFWYduwY3Ke0RQm2ZEfg90y9wZoyVQg4wGLhxVln_DTdSOA0XPvXOemhCLPdRZKt9hnM3SH2wEk6DzzE4WAgBV73L1hckeOHgOoaj9snmoVqJLHdaFXoXYoab3KvhFlwZ4ZK--99jsH2bbafv1fJjvpi-LivZ1nWlUSeFoaImuvQTtJVUdowwPDFIaNKUoFNMkVoyZYSSCjdtQ_WkVTXBiGI6Bg_nt8cYfnqdMt-HPpZ-iZMad3VDGlIX6vFMyRhSitrwY7QHEQeOET_J5Se5_KSLr-kfhrNs6g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2419452524</pqid></control><display><type>article</type><title>1022-P: Efficacy of Sliding Scale Insulin for Inpatient Glycemic Control in a Multinational Propensity-Matched Cohort Study</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>MIGDAL, ALEXANDRA ; FORTIN, CHARLIE ; GUO, YI ; HOCHBERG, IRIT ; MAGEE, MICHELLE F. ; PASQUEL, FRANCISCO J. ; UMPIERREZ, GUILLERMO E.</creator><creatorcontrib>MIGDAL, ALEXANDRA ; FORTIN, CHARLIE ; GUO, YI ; HOCHBERG, IRIT ; MAGEE, MICHELLE F. ; PASQUEL, FRANCISCO J. ; UMPIERREZ, GUILLERMO E.</creatorcontrib><description><![CDATA[Sliding scale insulin (SSI) continues to be widely used for glycemic management of inpatients with T2D despite condemnation in clinical guidelines. To confirm the accuracy of this clinical guideline recommendation, we determined the efficacy and safety of using SSI for the management hyperglycemia of non-critical patients with T2D in a large multinational, propensity-matched cohort study. A total of 53,516 patients with ICD 9/10 code of T2D were included in the dataset. Patients were categorized as having received SSI only vs. basal insulin, and were matched according to age, BMI, Charlson Comorbidity Index, and admission blood glucose (BG). Among patients with admission BG <180 mg/dL treated with SSI, 69% achieved and maintained good glycemic control (mean hospital BG <180 mg/dl), compared to 52% of patients treated with basal insulin (p <.001). Patients treated with basal insulin had higher rates of hypoglycemia than patients treated with SSI (30 vs. 16%, p <.001). There were no differences in rates of lactic acidosis, acute MI, pneumonia, or bacteremia (p=NS). A total of 14.93% of patients initially treated with SSI alone failed to achieve adequate glycemic control and were started on basal insulin during the hospital stay. Those who failed SSI had significantly higher admission BG (227.4±90 vs. 175.8±71 mg/dl), greater rates of CKD (31 vs. 24%), CHF (29 vs. 24%), CAD (35 vs. 31%), and higher Charlson score (4.3±2.7 vs. 3.8±2.7) than patients who remained well controlled on SSI alone (all, p<.001).
Conclusion: In a multicenter, international, propensity-matched cohort study, 69% of patients with T2D with admission BG <180 mg/dL treated with SSI achieved good glycemic control. Patients admitted with higher BG and greater comorbidities are more likely to fail treatment with SSI alone. These data suggest that SSI may be appropriate for patients with mild/moderate hyperglycemia, thus simplifying recommendations for inpatient glycemic management.]]></description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db20-1022-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Acidosis ; Bacteremia ; Blood glucose ; Clinical practice guidelines ; Diabetes ; Glucose monitoring ; Hyperglycemia ; Hypoglycemia ; Insulin ; Lactic acidosis ; Patients</subject><ispartof>Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)</ispartof><rights>Copyright American Diabetes Association Jun 1, 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>MIGDAL, ALEXANDRA</creatorcontrib><creatorcontrib>FORTIN, CHARLIE</creatorcontrib><creatorcontrib>GUO, YI</creatorcontrib><creatorcontrib>HOCHBERG, IRIT</creatorcontrib><creatorcontrib>MAGEE, MICHELLE F.</creatorcontrib><creatorcontrib>PASQUEL, FRANCISCO J.</creatorcontrib><creatorcontrib>UMPIERREZ, GUILLERMO E.</creatorcontrib><title>1022-P: Efficacy of Sliding Scale Insulin for Inpatient Glycemic Control in a Multinational Propensity-Matched Cohort Study</title><title>Diabetes (New York, N.Y.)</title><description><![CDATA[Sliding scale insulin (SSI) continues to be widely used for glycemic management of inpatients with T2D despite condemnation in clinical guidelines. To confirm the accuracy of this clinical guideline recommendation, we determined the efficacy and safety of using SSI for the management hyperglycemia of non-critical patients with T2D in a large multinational, propensity-matched cohort study. A total of 53,516 patients with ICD 9/10 code of T2D were included in the dataset. Patients were categorized as having received SSI only vs. basal insulin, and were matched according to age, BMI, Charlson Comorbidity Index, and admission blood glucose (BG). Among patients with admission BG <180 mg/dL treated with SSI, 69% achieved and maintained good glycemic control (mean hospital BG <180 mg/dl), compared to 52% of patients treated with basal insulin (p <.001). Patients treated with basal insulin had higher rates of hypoglycemia than patients treated with SSI (30 vs. 16%, p <.001). There were no differences in rates of lactic acidosis, acute MI, pneumonia, or bacteremia (p=NS). A total of 14.93% of patients initially treated with SSI alone failed to achieve adequate glycemic control and were started on basal insulin during the hospital stay. Those who failed SSI had significantly higher admission BG (227.4±90 vs. 175.8±71 mg/dl), greater rates of CKD (31 vs. 24%), CHF (29 vs. 24%), CAD (35 vs. 31%), and higher Charlson score (4.3±2.7 vs. 3.8±2.7) than patients who remained well controlled on SSI alone (all, p<.001).
Conclusion: In a multicenter, international, propensity-matched cohort study, 69% of patients with T2D with admission BG <180 mg/dL treated with SSI achieved good glycemic control. Patients admitted with higher BG and greater comorbidities are more likely to fail treatment with SSI alone. These data suggest that SSI may be appropriate for patients with mild/moderate hyperglycemia, thus simplifying recommendations for inpatient glycemic management.]]></description><subject>Acidosis</subject><subject>Bacteremia</subject><subject>Blood glucose</subject><subject>Clinical practice guidelines</subject><subject>Diabetes</subject><subject>Glucose monitoring</subject><subject>Hyperglycemia</subject><subject>Hypoglycemia</subject><subject>Insulin</subject><subject>Lactic acidosis</subject><subject>Patients</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNotkE1LAzEURYMoWKsr_0DApYzmY2bScSel1kKLhXbhLsR82JQ0qUlmMfjnTam8xXtwD4_LAeAeoydCKXtWXwRVGBFSrS_ACHe0qyhhn5dghBAmFWYduwY3Ke0RQm2ZEfg90y9wZoyVQg4wGLhxVln_DTdSOA0XPvXOemhCLPdRZKt9hnM3SH2wEk6DzzE4WAgBV73L1hckeOHgOoaj9snmoVqJLHdaFXoXYoab3KvhFlwZ4ZK--99jsH2bbafv1fJjvpi-LivZ1nWlUSeFoaImuvQTtJVUdowwPDFIaNKUoFNMkVoyZYSSCjdtQ_WkVTXBiGI6Bg_nt8cYfnqdMt-HPpZ-iZMad3VDGlIX6vFMyRhSitrwY7QHEQeOET_J5Se5_KSLr-kfhrNs6g</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>MIGDAL, ALEXANDRA</creator><creator>FORTIN, CHARLIE</creator><creator>GUO, YI</creator><creator>HOCHBERG, IRIT</creator><creator>MAGEE, MICHELLE F.</creator><creator>PASQUEL, FRANCISCO J.</creator><creator>UMPIERREZ, GUILLERMO E.</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20200601</creationdate><title>1022-P: Efficacy of Sliding Scale Insulin for Inpatient Glycemic Control in a Multinational Propensity-Matched Cohort Study</title><author>MIGDAL, ALEXANDRA ; FORTIN, CHARLIE ; GUO, YI ; HOCHBERG, IRIT ; MAGEE, MICHELLE F. ; PASQUEL, FRANCISCO J. ; UMPIERREZ, GUILLERMO E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c644-e09caf3a42ecaca36c3c972718f0ae25a429d7d24c7dfadcd15653e86d4210313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acidosis</topic><topic>Bacteremia</topic><topic>Blood glucose</topic><topic>Clinical practice guidelines</topic><topic>Diabetes</topic><topic>Glucose monitoring</topic><topic>Hyperglycemia</topic><topic>Hypoglycemia</topic><topic>Insulin</topic><topic>Lactic acidosis</topic><topic>Patients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MIGDAL, ALEXANDRA</creatorcontrib><creatorcontrib>FORTIN, CHARLIE</creatorcontrib><creatorcontrib>GUO, YI</creatorcontrib><creatorcontrib>HOCHBERG, IRIT</creatorcontrib><creatorcontrib>MAGEE, MICHELLE F.</creatorcontrib><creatorcontrib>PASQUEL, FRANCISCO J.</creatorcontrib><creatorcontrib>UMPIERREZ, GUILLERMO E.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MIGDAL, ALEXANDRA</au><au>FORTIN, CHARLIE</au><au>GUO, YI</au><au>HOCHBERG, IRIT</au><au>MAGEE, MICHELLE F.</au><au>PASQUEL, FRANCISCO J.</au><au>UMPIERREZ, GUILLERMO E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1022-P: Efficacy of Sliding Scale Insulin for Inpatient Glycemic Control in a Multinational Propensity-Matched Cohort Study</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2020-06-01</date><risdate>2020</risdate><volume>69</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract><![CDATA[Sliding scale insulin (SSI) continues to be widely used for glycemic management of inpatients with T2D despite condemnation in clinical guidelines. To confirm the accuracy of this clinical guideline recommendation, we determined the efficacy and safety of using SSI for the management hyperglycemia of non-critical patients with T2D in a large multinational, propensity-matched cohort study. A total of 53,516 patients with ICD 9/10 code of T2D were included in the dataset. Patients were categorized as having received SSI only vs. basal insulin, and were matched according to age, BMI, Charlson Comorbidity Index, and admission blood glucose (BG). Among patients with admission BG <180 mg/dL treated with SSI, 69% achieved and maintained good glycemic control (mean hospital BG <180 mg/dl), compared to 52% of patients treated with basal insulin (p <.001). Patients treated with basal insulin had higher rates of hypoglycemia than patients treated with SSI (30 vs. 16%, p <.001). There were no differences in rates of lactic acidosis, acute MI, pneumonia, or bacteremia (p=NS). A total of 14.93% of patients initially treated with SSI alone failed to achieve adequate glycemic control and were started on basal insulin during the hospital stay. Those who failed SSI had significantly higher admission BG (227.4±90 vs. 175.8±71 mg/dl), greater rates of CKD (31 vs. 24%), CHF (29 vs. 24%), CAD (35 vs. 31%), and higher Charlson score (4.3±2.7 vs. 3.8±2.7) than patients who remained well controlled on SSI alone (all, p<.001).
Conclusion: In a multicenter, international, propensity-matched cohort study, 69% of patients with T2D with admission BG <180 mg/dL treated with SSI achieved good glycemic control. Patients admitted with higher BG and greater comorbidities are more likely to fail treatment with SSI alone. These data suggest that SSI may be appropriate for patients with mild/moderate hyperglycemia, thus simplifying recommendations for inpatient glycemic management.]]></abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db20-1022-P</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1) |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_2419452524 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Acidosis Bacteremia Blood glucose Clinical practice guidelines Diabetes Glucose monitoring Hyperglycemia Hypoglycemia Insulin Lactic acidosis Patients |
| title | 1022-P: Efficacy of Sliding Scale Insulin for Inpatient Glycemic Control in a Multinational Propensity-Matched Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A21%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1022-P:%20Efficacy%20of%20Sliding%20Scale%20Insulin%20for%20Inpatient%20Glycemic%20Control%20in%20a%20Multinational%20Propensity-Matched%20Cohort%20Study&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=MIGDAL,%20ALEXANDRA&rft.date=2020-06-01&rft.volume=69&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db20-1022-P&rft_dat=%3Cproquest_cross%3E2419452524%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2419452524&rft_id=info:pmid/&rfr_iscdi=true |